Vaxart, Inc.
VXRT- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000072444
No open-market purchases or sales by Vaxart, Inc. insiders were filed in the last 90 days; 4 institutions reported holding it in 13F filings for Q2 2026, worth $39.0K in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Vaxart, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 100
- −2 vs. Q1 2024
- Shares held
- 40.5M
- +306.2K (+0.8%) vs. Q1 2024
- Total value
- $27.0M
- −$25.2M (−48.3%) vs. Q1 2024
- New holders
- 22
- 21 more added
- Sold out
- 24
- 22 more reduced
2 institutions that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VXRT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 4 | $39.0K |
| Q1 2026 | 5 | $34.2K |
| Q4 2025 | 5 | $22.2K |
| Q3 2025 | 17 | $839.9K |
| Q2 2025 | 98 | $10.3M |
| Q1 2025 | 92 | $11.1M |
| Q4 2024 | 93 | $23.7M |
| Q3 2024 | 100 | $31.9M |
| Q2 2024 | 100 | $27.0M |
| Q1 2024 | 104 | $52.3M |
| Q4 2023 | 87 | $9.38M |
| Q3 2023 | 96 | $13.9M |
| Q2 2023 | 111 | $21.1M |
| Q1 2023 | 109 | $25.8M |
| Q4 2022 | 132 | $42.6M |
| Q3 2022 | 143 | $110.7M |
| Q2 2022 | 146 | $155.6M |
| Q1 2022 | 148 | $226.3M |
| Q4 2021 | 147 | $267.9M |
| Q3 2021 | 141 | $297.5M |
| Q2 2021 | 143 | $260.6M |
| Q1 2021 | 159 | $195.1M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Vaxart, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 0 | $0 | 0.00% | −15,384,615−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −1,498,564−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −769,467−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −529,578−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −215,977−100.0% | Sold out |
| Point72 Asia (Singapore) Pte. Ltd. | 0 | $0 | 0.00% | −208,046−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −189,160−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −174,606−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −166,114−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −135,595−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −109,976−100.0% | Sold out |
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −91,765−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −78,439−100.0% | Sold out |
| Omers Administration Corp | 0 | $0 | 0.00% | −70,400−100.0% | Sold out |
| CTC Alternative Strategies, Ltd. | 0 | $0 | 0.00% | −49,300−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −48,980−100.0% | Sold out |
| Brevan Howard Capital Management LP | 0 | $0 | 0.00% | −44,864−100.0% | Sold out |
| Jefferies Financial Group Inc. | 0 | $0 | 0.00% | −28,100−100.0% | Sold out |
| DRW Securities, LLC | 0 | $0 | 0.00% | −15,200−100.0% | Sold out |
| Catalyst Funds Management Pty Ltd | 0 | $0 | 0.00% | −14,870−100.0% | Sold out |
| Headlands Technologies LLC | 0 | $0 | 0.00% | −9,213−100.0% | Sold out |
| NBC Securities, Inc. | 0 | $0 | 0.00% | −800−100.0% | Sold out |
| Old Point Trust & Financial Services N A | 0 | $0 | 0.00% | −250−100.0% | Sold out |
| Macquarie Group Ltd | 0 | $0 | 0.00% | −4,985−100.0% | Sold out |
| Grey Street Capital, LLC | – | – | – | – | Not filed |
| InterOcean Capital Group, LLC | – | – | – | – | Not filed |